An experimental vaccine with pulsed HER2 peptides and DCs polarized against HER2 (HER2-DC1) was capable of potentializing the TH1-dependent immune response against this antigen in subjects with both HER2-positive DCIS and HER2-positive early invasive BC, and improved pCR [86,87]. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.